Liquid Chromatography-Tandem Mass Spectrometry Analysis Demonstrates a Decrease in Porins and Increase in CMY-2

Dimard E Foudraine1, Camiel N M Aarents1, Agnes A Wattel1

  • 1Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center (Erasmus MC), Rotterdam, Netherlands.

Insights

Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases contribute to carbapenem resistance in E. coli. Decreased porin expression is an early resistance mechanism, detectable by LC-MS/MS.

Area of Science:

  • Microbiology
  • Biochemistry
  • Genetics

Background:

  • Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases can confer carbapenem resistance in Enterobacterales.
  • Mechanisms include binding carbapenems and reduced antibiotic influx due to decreased porin expression.

Purpose of the Study:

  • Develop a targeted LC-MS/MS assay for detecting E. coli porins (OmpC, OmpF), AmpC β-lactamase, and CMY-2 β-lactamase.
  • Investigate early resistance mechanisms to meropenem in E. coli.

Main Methods:

  • Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay development.
  • Culturing E. coli isolates with increasing meropenem concentrations.
  • Analysis of resistant mutants using LC-MS/MS, Western blotting, and whole genome sequencing.

Main Results:

  • Decreased OmpC and/or OmpF expression was the initial step towards meropenem resistance in five strains.
  • Increased CMY-2 production contributed to higher Minimum Inhibitory Concentrations (MICs) in four strains.
  • One strain showed increased resistance likely due to elevated CTX-M-15 production.

Conclusions:

  • The developed LC-MS/MS assay is effective for (semi-)quantitative analysis of CMY-2-like β-lactamases and porins within 4 hours.
  • Targeted LC-MS/MS holds clinical value for early detection of non-carbapenemase-producing carbapenem-resistant E. coli.